A commentary published in Nature argues that current epidemic-tracking methods—event-based monitoring, genomic sequencing, and syndromic surveillance—fail to catch pathogens that present with atypical or evolving symptoms. The authors point to the ongoing Ebola outbreak, the 2020 COVID-19 pandemic, and the 2022 mpox outbreak as examples where unusual symptom presentations delayed detection and containment. They propose five overlooked steps to improve early identification of new epidemics.
nature.com
· 2026-11-02
Measles infections quietly increased in multiple countries even as COVID-19 remained the primary focus of public health systems and media coverage. The resurgence reflects disruptions to routine vaccination programs during the pandemic period.
nature.com
· 2026-11-02
Wellcome's third Global Monitor survey, released October 10, finds trust in science and researchers has fallen since the COVID-19 pandemic, with notable variation by country and region. The survey, which for the first time asked about artificial intelligence, also found links between people's financial security and their trust in science, and between confidence in local health-care access and trust in science overall.
nature.com
· 2026-10-28
Recent polling cited shows that 38 percent of U.S. adults report being estranged from at least one family member, a trend that researchers say has grown more visible since the Covid-19 pandemic. The data suggests this personal rupture is increasingly spilling into workplaces, affecting employees' focus and wellbeing on the job.
fastcompany.com
· 2026-10-13
PopVax dosed the first participants in a Phase 1 trial of PVX-001, a broadly protective COVID-19 vaccine candidate, in Melbourne on 31 August 2026. The trial will enroll 36 healthy adults to test safety and immune response breadth; as of 6 October, 14 participants had been dosed with no serious adverse events reported. The vaccine uses PopVax's own protein design, mRNA-VLP architecture, and fridge-stable lipid nanoparticle delivery, built in-house over 4.5 years, and will be open-sourced once the trial concludes.
chronicles.popvax.com
· 2026-10-10
Researchers at the University of Oxford launched a project in 2022 to explore how academic teams can produce timely scientific insights in partnership with various stakeholders. Their experiments aim to demonstrate more agile and transparent research practices suited for urgent decision-making contexts. These efforts follow the successful COVID-19 response, which showcased rapid scientific collaboration and innovation.
nature.com
· 2026-10-06
Verifact Markets, a startup incubated by Peter Wokwicz's Positron Capital Management, launched Friday with trading on 'disputed facts' rather than future events. Initial markets let traders bet on whether Jeffrey Epstein died by suicide, whether State Farm intentionally delayed LA wildfire claims, and whether Covid-19 originated from the Wuhan Institute of Virology, with 'true' currently priced at 76 cents on that question.
wired.com
· 2026-10-05
The CDC has begun allowing states to order 2026–2027 COVID-19 vaccines through the Vaccines for Children program, ending a delay of nearly a month despite FDA approval of the shots in late August. HHS initially said procurement decisions had not been finalized, and an unnamed source told The Washington Post the holdup partly stemmed from unfinished clinical guidance requiring outside expert review.
arstechnica.com
· 2026-09-24
The CDC has not finalized procurement decisions allowing states to order this season's COVID-19 vaccines through the Vaccines for Children program, which covers roughly 52 percent of US children who are uninsured, underinsured, Medicaid-eligible, or Indigenous. The delay also affects at least 11 states and one US territory that use VFC contracts to buy vaccines universally for all children regardless of insurance status. HHS, led by Robert F. Kennedy Jr., confirmed the procurement decisions remain unfinished but did not explain the reason for the delay.
arstechnica.com
· 2026-09-23
A new analysis argues that how companies decide where employees work matters as much as the final policy itself. It notes that more than six years after COVID-19 began, over one in five U.S. workers able to work remotely still do so full-time or part-time.
fastcompany.com
· 2026-09-23
A letter in Nature responds to a feature on AI-enabled biological threats by arguing that biosecurity thinking is too narrowly focused on mortality. The author points to severe ME/CFS and post-COVID disability as evidence that a biological event can devastate a population's functional capacity without killing large numbers of people.
nature.com
· 2026-09-22
A newly compiled dataset tracking all-cause mortality across 134 countries indicates that official COVID-19 death tolls were vastly understated, with excess deaths pointing to more than 6 million uncounted fatalities worldwide. The analysis suggests roughly half of governments either failed to accurately measure or deliberately concealed the true scale of pandemic deaths.
gizmodo.com
· 2026-09-10
GoKawiil